Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.

EJHaem · 2022 · PMC9176062 · PMID 35846221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In arm A, GI disorders showed a trend suggesting a dose effect, while other TEAEs (including neutropenia and thrombocytopenia) showed improvement with intermittent dosing of CC‐122 (Table S3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.